CD19 mutations including frame-shift insertion or deletions, in-frame deletion, non-sense mutations, and splice-site single nucleotide variants (SNVs) were observed in five of seven R/R B-ALL patients who had CD19-negative relapse after blinatumomab treatment, suggesting CD19 mutations were common. Here, CD19 is linked to acute lymphoblastic leukemia.